Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam tosilate plus remifentanil vs midazolam plus remifentanil for sedation in mechanically ventilated patients with mild renal insufficiency
ChiCTR2200066937Phase 4Not yet recruiting
- Sponsor
- Shanxi Provincial People's Hospital
- Start
- Dec 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, midazolam and remifentanil in Renal Insufficiency (RI) (2 arms), sponsored by Shanxi Provincial People's Hospital. Primary endpoint: Complete recovery time after stopping medication. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
remimazolammidazolamremifentanil
03
Conditions
Renal Insufficiency (RI)
Beyond the preview
Go deeper on ChiCTR2200066937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066937.